During the last decade, however, the interest in the role of sclerostin in the pathophysiological context of CKD has been growing, in particular its interaction with PTH and their potential reciprocal inverse effect on bone turnover and mineralization [20,33]. Here, SOST is linked to chronic kidney disease.